About this trial
Endometriosis is a chronic inflammatory disease affecting approximately 10% of women in their reproductive years. It is characterized by the presence of endometrial-like tissue outside the uterine cavity. Current treatment options include hormonal therapies or surgical excision of the endometriotic lesions. Although these interventions often lead to a significant symptom relief, some patients still experience persistent pain or treatment-related adverse effects. Consequently, the management of dysmenorrhea and improvement of quality of life in patients with endometriosis remain a clinical challenge.
Desloratadine is widely used for the treatment of allergic rhinitis or chronic urticaria. Recent studies suggest that desloratadine may also possess analgesic and anti-inflammatory properties. So far, however, no clinical studies have investigated its potential therapeutic effects in patients with endometriosis.
Therefore, the present study aims to provide the first clinical assessment of the efficacy, safety and tolerability of desloratadine in patients with endometriosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female patients aged 18-50
By imaging (sonography or MRI) or surgery last 10 years confirmed endometriosis
EHP-30 Score > 40
Disqualifiers
Subject is unable or unwilling to participate
History of malignant diseases
Current immunosuppressant treatment
History of allergies and/or usage of antihistaminic treatments
Trial design
Parallel
Treatments tested in this trial
Desloratadine
Drug5mg daily
Placebo
DrugPlacebo
Treatment groups
Trial outcomes
Primary outcomes
Change in the Endometriosis-Health-Profile-30 (EHP-30) Score
The Score is used to measure the impact of Endometriosis on the quality of life. It is standardised on a scale from 0 to 100. 0 indicates the best health status whereas 100 indicates the worst health status.
Secondary outcomes
Change in Dysmenorrhea using the visual analogue scale (0-10)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: